Market Overview:
The global purpura therapy drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of purpura, rising awareness about purpura therapies, and technological advancements in the field of purpura therapies. On the basisof application,the market is segmented into hospital use, clinic use household use other uses).
Product Definition:
Purpura Therapy Drugs are a class of drugs that are used to treat purpura. Purpura is a condition that causes red or purple spots on the skin due to bleeding underneath the surface. Purpura Therapy Drugs work by helping to reduce inflammation and promote clotting. They may be prescribed in cases of mild purpura, as well as more severe cases where there is significant bleeding.
Allergic Purpura:
Allergic purpura is a rare, but serious medical condition that causes the body's immune system to attack and damage blood vessels. This leads to leakage of blood cells, proteins, and other substances called antigens into the skin, causing redness and swelling. In some cases allergic purpura can cause life-threatening complications such as kidney failure or heart attack.
Thrombocytopenic Purpura:
Thrombocytopenic purpura (TPP) is a rare disease characterized by the destruction of platelets due to an autoimmune process. The drug used for treatment of TPP, Daclizumab, works by decreasing the immune response and helps restore blood clotting. According to NCBI article, around 5-10 cases are registered per million annually globally.
Daclizumab was approved in 2007 in Canada and 2008 in U.S.
Application Insights:
The other application segment held the largest share of the global purpura therapy drugs market in 2017. Other applications include research studies, domestic use (household), and other clinical trials. The household application segment is expected to witness significant growth over the forecast period owing to increasing awareness about treatment options for rare diseases among high-income countries such as U.S., Canada, and Germany.
Household purpura is most commonly associated with pregnancy complications or autoimmune disease that affects a family member previously or currently undergoing treatment with a medication for another condition (hypotheticalall).
Regional Analysis:
Europe accounted for the largest revenue share in 2017. The presence of key purpura treatment manufacturers and well-developed healthcare infrastructure are some of the factors responsible for its dominance. In addition, increasing prevalence of thrombocytopenic purpura is also driving demand in this region. According to an article published by NCBI, around 1 million cases were reported annually from Europe between 2010 and 2012.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases are responsible for over 63% of all deaths worldwide. This number is expected to increase to over 75% by 2030. This presents a huge opportunity for purpura therapy drugs market as these drugs can help in managing and treating chronic diseases effectively.
- Growing awareness about purpura therapy drugs: There is growing awareness among people about the benefits of using purpura therapy drugs for managing and treating various health conditions, both chronic and acute ones alike. As a result, more people are now turning towards these drugs for relief from their symptoms, which is likely to drive growth in this market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Purpura Therapy Drugs Market Research Report
By Type
Allergic Purpura, Thrombocytopenic Purpura
By Application
Hospital Use, Clinic Use, Household, Other
By Companies
Bristol-Myers Squibb Company, Pfizer Inc, GlaxoSmithKline Plc, Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc, Ablynx NV, Biogen Inc, KM Biologics, Lee's Pharmaceutical Holdings Ltd, Omeros Corp, Shire Plc, Roch
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Purpura Therapy Drugs Market Report Segments:
The global Purpura Therapy Drugs market is segmented on the basis of:
Types
Allergic Purpura, Thrombocytopenic Purpura
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Use, Clinic Use, Household, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb Company
- Pfizer Inc
- GlaxoSmithKline Plc
- Novartis AG
- Hovione
- Sanofi Winthrop Industrie S.A.
- Hoffman-L Roche
- Amgen Inc
- Grifols Biologicals Inc
- Ablynx NV
- Biogen Inc
- KM Biologics
- Lee's Pharmaceutical Holdings Ltd
- Omeros Corp
- Shire Plc
- Roch
Highlights of The Purpura Therapy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Allergic Purpura
- Thrombocytopenic Purpura
- By Application:
- Hospital Use
- Clinic Use
- Household
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Purpura Therapy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Purpura therapy drugs are medications used to treat various types of purpura, including Henoch-Schu00f6nlein purpura (HSP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). These medications work by blocking the release of histamine from cells in the skin.
Some of the major players in the purpura therapy drugs market are Bristol-Myers Squibb Company, Pfizer Inc, GlaxoSmithKline Plc, Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc, Ablynx NV, Biogen Inc, KM Biologics, Lee's Pharmaceutical Holdings Ltd, Omeros Corp, Shire Plc, Roch.
The purpura therapy drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Purpura Therapy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Purpura Therapy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Purpura Therapy Drugs Market - Supply Chain
4.5. Global Purpura Therapy Drugs Market Forecast
4.5.1. Purpura Therapy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Purpura Therapy Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Purpura Therapy Drugs Market Absolute $ Opportunity
5. Global Purpura Therapy Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Purpura Therapy Drugs Market Size and Volume Forecast by Type
5.3.1. Allergic Purpura
5.3.2. Thrombocytopenic Purpura
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Purpura Therapy Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Purpura Therapy Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Use
6.3.2. Clinic Use
6.3.3. Household
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Purpura Therapy Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Purpura Therapy Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Purpura Therapy Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Purpura Therapy Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Purpura Therapy Drugs Demand Share Forecast, 2019-2026
9. North America Purpura Therapy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Purpura Therapy Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Purpura Therapy Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Use
9.4.2. Clinic Use
9.4.3. Household
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Purpura Therapy Drugs Market Size and Volume Forecast by Type
9.7.1. Allergic Purpura
9.7.2. Thrombocytopenic Purpura
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Purpura Therapy Drugs Demand Share Forecast, 2019-2026
10. Latin America Purpura Therapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Purpura Therapy Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Purpura Therapy Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Use
10.4.2. Clinic Use
10.4.3. Household
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Purpura Therapy Drugs Market Size and Volume Forecast by Type
10.7.1. Allergic Purpura
10.7.2. Thrombocytopenic Purpura
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Purpura Therapy Drugs Demand Share Forecast, 2019-2026
11. Europe Purpura Therapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Purpura Therapy Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Purpura Therapy Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Use
11.4.2. Clinic Use
11.4.3. Household
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Purpura Therapy Drugs Market Size and Volume Forecast by Type
11.7.1. Allergic Purpura
11.7.2. Thrombocytopenic Purpura
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Purpura Therapy Drugs Demand Share, 2019-2026
12. Asia Pacific Purpura Therapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Purpura Therapy Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Purpura Therapy Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Use
12.4.2. Clinic Use
12.4.3. Household
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Purpura Therapy Drugs Market Size and Volume Forecast by Type
12.7.1. Allergic Purpura
12.7.2. Thrombocytopenic Purpura
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Purpura Therapy Drugs Demand Share, 2019-2026
13. Middle East & Africa Purpura Therapy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Purpura Therapy Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Purpura Therapy Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Use
13.4.2. Clinic Use
13.4.3. Household
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Purpura Therapy Drugs Market Size and Volume Forecast by Type
13.7.1. Allergic Purpura
13.7.2. Thrombocytopenic Purpura
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Purpura Therapy Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Purpura Therapy Drugs Market: Market Share Analysis
14.2. Purpura Therapy Drugs Distributors and Customers
14.3. Purpura Therapy Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hovione
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi Winthrop Industrie S.A.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hoffman-L Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amgen Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Grifols Biologicals Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Ablynx NV
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Biogen Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. KM Biologics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Lee's Pharmaceutical Holdings Ltd
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Omeros Corp
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Shire Plc
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Roch
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
